Exceeding 4,000 IU daily can be dangerous
Some patients report benefit
Peptides in this group include an alphabet soup of injectable compounds, including BPC-157, thymosin alpha, GHK-Copper and many more
Its best for people who train hard, recover slowly, or deal with old injuries
GLP-1 Story Continues Here are the key figures since Q2 2024: Q2 2024: GLP-1 revenue: $12 million Total revenue: $325 million Share of GLP-1 revenue: 4 % Q3 2024: GLP-1 revenue: $55 million* Total revenue: $441 million Share of GLP-1 revenue: 12 % Q4 2024: GLP-1 revenue: $162 million* Total revenue: $488 million Share of GLP-1 revenue: 33 % Q1 2025: GLP-1 revenue: $ 230 million Total revenue: $596 million Share of GLP-1 revenue: 39 % Q2 2025: GLP-1 revenue: $190 million Total revenue: $545 million Share of GLP-1 revenue: 35 % * Estimate based on the $229M GLP-1 revenue for FY 2024 Revenue Momentum Stalls Amid GLP-1 Reliance Historically Hims has issued conservative guidance and then surpassed the top end of its range
Dedicated GLP-1 trackers beat generalists on everything that surrounds the medication: dose timing, injection sites, symptom severity beside doses, and estimated medication levels
